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Losartan (Losartanum) belongs to sartans, i.e.,
angiotensin receptor blockers recommended in
hypertension therapy. 
Quinapril belongs to the group of angiotensin-
converting enzyme inhibitors. It is used in a form of
prodrug. Its active form is quinaprilat which is
formed as a result of biotransformation in the liver.
It is recommended in therapy of hypertension and
heart failure. In hypertension treatment it is used
both in monotherapy and in combined therapy.
Hydrochlorothiazide is qualified to the group
of saluretics, i.e., thiazide diuretics. In terms of
chemical structure it is sulfonamide derivative. This
drug exhibits diuretic and blood pressure lowering
activity.
Main indication for this drug administration is
hypertension (primary and renovascular). In hyper-
tension therapy, this drug is used both in monother-
apy and in therapy combined with other antihyper-
tensive drugs of various targets. An application of
antihypertensive drugs of separate activity mecha-
nisms allows to obtain synergistic effect and in a
consequence to increase their antihypertensive
activity.
Numerous analytical methods were used in the
studies on losartan, quinapril and hydrochlorothi-
azide analysis in pharmaceutical preparations and
body fluids (1).
Hydrochlorothiazide and photodegradation
products were determined spectrophotometrically
using first derivative, and high performance liquid
chromatography (HPLC) method often combined
with mass spectrometry (2-5). Thin layer chro-
matography (TLC) method was used in an analysis
of hydrochlorothiazide and other substances from
diuretics group (6). Good results in hydrochlorothi-
azide determinations in pharmaceutical preparations
were obtained using voltammetry method (7),
HPTLC (8), reversed phase high performance liquid
chromatography (RP-HPLC) (9) or capillary elec-
trophoresis (10) methods 
Liquid chromatography method with fluorimet-
ric (11) or mass detection (12, 13) were used in losar-
tan potassium determination in biological material. 
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Abstract: Two methods, spectrophotometric and chromatographic-densitometric ones, were developed for
determination of losartan potassium, quinapril hydrochloride and hydrochlorothiazide in pharmaceutical prepa-
rations. Spectrophotometric method involved derivative spectrophotometry and zero order spectrophotometry.
The measurements were carried out at λ = 224.0 nm for quinapril, λ = 261.0 nm for hydrochlorothiazide and λ
= 270.0 nm for losartan when the derivative spectrophotometry was applied and λ = 317.0 nm when zero order
spectrophotometry was applied for the determination of hydrochlorothiazide. In chromatographic-densitomet-
ric studies high performance thin layer chromatography (HPTLC) plates were used as stationary phase and a
mixture of solvents n-butanol : acetic acid : water (15 : 5 : 1, v/v/v) as mobile phase. Under the established con-
ditions good resolution of examined constituents was obtained. Retardation factor for quinapril hydrochloride
was Rf ~ 0.70, for losartan potassium Rf ~ 0.85 and for hydrochlorothiazide Rf ~ 0.78. The developed methods
are characterized by high sensitivity and accuracy. For quantitative analysis, densitometric measurements were
carried out at λ = 218.0 nm for quinapril, λ = 275.0 nm for hydrochlorothiazide and λ = 232.0 nm for losartan.
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Quinapril, and other angiotensin convertase
inhibitors, was determined using voltammetry
method (14). Spectrophotometric (15, 16) and
HPTLC methods (17) were used for studies in com-
plex drugs containing hydrochlorothiazide.
Pharmacologically active quinapril metabolite in
blood serum was determined using ultra high per-
formance liquid chromatography-electrospray ion-
ization mass spectrometry (UHPLC-MS) (18).
This research aimed at a development of the
method of hydrochlorothiazide, as well as quinapril
and losartan co-present in complex drugs, determi-
nation with an application of derivative spectropho-
tometry and high performance thin layer chromatog-
raphy. 
The study included pharmaceutical prepara-
tions in which one of the components is
hydrochlorothiazide and the second is one of the
substances of antihypertensive activity, i.e., losartan
potassium or quinapril hydrochloride. Accuzide 20
containing 20.0 mg of quinapril and 12.50 mg of
hydrochlorothiazide, as well as Lorista® H prepara-
tion containing 50 mg of potassium losartan and
12.50 mg of hydrochlorothiazide were used in the
studies.
EXPERIMENTAL
Apparatus
Spectrophotometer UV-VIS Cary 100 Varian
(Australia), quartz cuvettes of a layer thickness 1
cm. Computer ñ Dell Optiplex 755; Intel(R)
Core(TM)2 Duo CPU; E4500 @ 2.20 GHz; 1.18
GHz, 1.95 GB Ram (Microsoft Office 2006,
Statistica 7.1 edition 2007). Applicator for samples
application LINOMAT 4; Camag (Muttenz,
Switzerland). Densitometer TLC- Scanner 3 with
WinCats software version 1.3.4; Camag (Muttenz,
Switzerland). Microsyringe of a volume of 100 µL
(Hamilton Comp. Reno, USA). Chromatographic
chamber 23 ◊ 9 ◊ 11 cm Nano-Desaga (Germany). 
Materials
Reference standards: losartan potassium,
quinaprilum, hydrochlorothiazide. Tablets: Lorista®
H (KRKA), Accuzide® 20 (Pfizer). Reagents of ana-
lytical grade quality: methanol, n-butanol, acetic
acid. HPTLC plates 60F254 No 1.05548.0001
(Merck-Darmstadt, Germany).
Standard solutions
For spectrophotometric method: Losartan
potassium (19.3 mg of losartan potassium was
weighed and completed with methanol up to the vol-
ume of 10.0 mL). Quinapril hydrochloride (19.6 mg
of quinapril hydrochloride was weighed and com-
pleted with methanol up to the volume of 10 mL).
Hydrochlorothiazide (12.4 mg of hydrochlorothi-
azide was weighed and completed with methanol up
to the volume of 10 mL). 
For chromatographic-densitometric analysis:
Methanol standard solutions for chromatographic-
densitometric analysis had the following concentra-
tions: losartan 0.44 mg/mL, quinapril 0.38 mg/mL
and hydrochlorothiazide 0.52 mg/mL.
Sample solutions
Ten tablets of the studied preparations were
powdered in a porcelain mortar. Weighed amounts
of samples in a range of 129.8 to 240.2 mg
(Accuzide 20), 99.5 to 271.3 mg (Lorista® H) were
extracted using 10 mL of methanol, shaking for 15
min and centrifuged (1500 rpm). Solutions obtained
directly after extraction and centrifugation were
used in chromatographic-densitometric analysis,
while in order to perform spectrophotometric analy-
sis, the solutions obtained were diluted in a ratio of
1 : 100.
Spectrophotometric analysis
The absorption spectra in the range from 200 to
400 nm were registered for standard solutions and
studied samples solutions in the presence of
methanol. Spectra of zero order were transformed in
the first order derivative (D1). The concentration of
studied substances in pharmaceutical preparations
was calculated using straight line equation based on
the value of derivative and an absorbance read out at
suitable wavelengths at λ = 224.0 nm and λ = 261.0
nm for quinapril and hydrochlorothiazide (in the
case of active substances content determination in
Accuzide 20 preparation), respectively, and λ =
270.0 nm for losartan potassium and λ = 317.0 nm
for hydrochlorothiazide (determined in Lorista ®H
preparation). 
Chromatographic-densitometric analysis 
Suitable standard solutions and studied sam-
ples were spread in amount of 3 mL in a form of 10
mm band using an applicator on HPTLC chromato-
graphic plates (10 ◊ 10 cm). Chromatograms were
developed in a chromatographic chamber saturated
with mobile phase composed of n-butanol : acetic
acid : water ñ 15 : 5 : 1 (v/v/v), they were developed
to a height of 9.5 cm and dried at room temperature.
Densitometric registration was performed after
plates drying, with the following wavelengths: λ =
218 nm for quinapril, λ = 275 nm for hydrochlorothi-
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Figure 1. The zero order absorption spectra for quinapril (A), hydrochlorothiazide (B), mixture (C)
Figure 2. The zero order absorption spectra for losartan (A), hydrochlorothiazide (B), mixture (C)
Figure 3. The first (D1) derivative spectra for quinapril (A), hydrochlorothiazide (B), mixture (C)
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azide and λ = 232 nm for losartan. The wavelength
at which densitometric detection was performed,
was selected based on spectra registered directly
from chromatogram. 
Content of active compounds in the prepara-
tions was calculated comparing the areas of ana-
lyzed sample peaks with an area of peaks of stan-
dard substances of known concentration. 
Validation study
Validation of the methods was performed
according to ICH requirements (19)
Specificity: Due to lack of data concerning
placebo composition, the comparative spectrophoto-
metric studies were performed for model solutions
(Rm) and pharmaceutical forms being a subject of
the study (Pf). Solutions of a comparable composi-
Figure 4. The first (D1) derivative spectra for losartan (A), hydrochlorothiazide (B), mixture (C)
Figure 5. Absorption spectra of hydrochlorothiazide, quinapril and losartan registered directly from the chromatogram
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tion containing 75, 100 and 125% of particular com-
pound were prepared. Measurements of derivatives
values were performed at selected wavelengths.
Specificity of the method for an analyte was deter-
mined comparing the values of absorbance and
derivatives for standard solutions and pharmaceuti-
cal preparations. 
Specificity of chromatographic-densitometric
method was verified by a comparison of retardation
factors (Rf) for studied substances and calculation of
resolution of registered peaks (Rs ñ resolution fac-
tor).
Linearity: For spectrophotometric method, lin-
earity is maintained within the studied ranges of
concentrations. The equations of linear regression
characterizing the points of straight line cut, correla-
tion coefficient and statistical tests were used for the
results assessment. In chromatographic-densitomet-
ric method, linearity assessment was performed by
measurements for standard solutions in concentra-
tion range of 0.0078 ñ 1.00 mg/mL for hydrochloro-
thiazide, 0.0313 ñ 2.00 mg/mL for quinaprilum and
0.0306 ñ 0.49 mg/mL for losartan. 
Limit of detection (LOD) and limit of quantifi-
cation (LOQ): For both methods, limit of detection
and limit of quantification were calculated using
values of statistical parameters for suitable calibra-
tion curves according to the following formula:
LOD = 3.3Sy/a and LOQ = 10.0Sy/a 
where Sy ñ standard estimation error, a ñ gradient of
a straight line.
Recovery: Determination of recovery percent-
age aims to determine an accuracy of the method,
i.e., accordance between the real value and a value
obtained as a result of analysis. It should be in the
range of 95-105%. Recovery for particular compo-
nents was provided as percents based on determined
concentration of analyte which was added to the
samples in amount from 80% to 120% with respect
to the declared amounts. 
Precision: Five assays were performed in order
to determine the precision of the method. Amount of
3 µL of analyzed component solution was spread on
chromatographic plate. In the next stage, the plates
were developed in the developing mobile phase, and
then densitometric analysis was performed. The
areas of peaks were compared in order to determine
the precision. 
RESULTS AND DISCUSSION
Combination of pharmacologically active com-
pounds in complex drugs is justified in terms of clin-
ical practice, since it often allows to obtain
improved therapeutic effects with increased undesir-
able activity. It is understandable that pharmacolog-
ical properties and technological aspect with respect
Figure 6. Densitogram of examined preparations solutions: quinapril (1) Rf ~ 0.70, hydrochlorothiazide (2) Rf ~ 0.78, losartan (3) Rf ~ 0.85 
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to components stability and pharmaceutical
availability are considered at the stage of com-
ponents selection. 
The components occurring in the studied
drug have similar physicochemical properties,
and their absorption spectra registered using
zero order spectrophotometric method inter-
fere with each other, which prevents its appli-
cation in direct analysis of quinapril, losartan
and hydrochlorothiazide. 
This problem is not observed in the case
of an application of derivative spectrophotom-
etry method, which was developed for the
needs of direct analysis of components being a
subject of the research. Equally good results
may be obtained using chromatographic-den-
sitometric method in an analysis of selected
preparations. The spectra of zero order in the
range of 200 ñ 400 nm were registered in the
first stage of the research for suitable standard
solutions containing active substances studied.
Spectrophotometric measurements were per-
formed in the presence of methanol as a refer-
ence substance, and their results are presented
in Figures 1 and 2. 
Analyzing the course of absorption spec-
tra of quinapril and hydrochlorothiazide mix-
ture (Fig. 1) as well as losartan and hydro-
chlorothiazide (Fig. 2), a clear interference of
absorption maxima in the range of 200-300 nm
was noted, which prevents direct analysis of
the studied substances. Transformation of the
obtained spectra into the first order derivative
curves (Figs. 3, 4) and an application of zero-
crossing technique allowed to determine the
wavelengths at which interference phenomena
were not observed.
For quantitative analysis purposes, suit-
able wavelengths were selected: λ = 224 nm
for quinapril and λ = 261 nm for
hydrochlorothiazide in their mixture. The
analysis of losartan and hydrochlorothiazide
mixture was possible with an application of
relationship D1 = f(c) at λ = 270 nm for deter-
mination of losartan, and relationship A = f(c)
λ = 317 nm for hydrochlorothiazide determi-
nation. The results obtained allow to conclude
that the method of the first order derivative
spectrophotometry (D1) or combination of
derivative spectrophotometry method and zero
order spectrophotometry in case of concurrent
determination of losartan potassium and
hydrochlorothiazide, allows to perform an
analysis of active substances in the studiedTa
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forms of drugs. Due to characteristic course of
derivative curves and absence of zero sites, which
would have been used for determination of compo-
nents in three-components mixture, especially with
respect to losartan potassium, the method of deriva-
tive spectrophotometry is not recommended for such
mixtures analysis. This is not a factor determining
its usefulness in quantitative analysis of these active
substances, since studied substances are not
observed in three component combination in a form
of a drug. The chromatographic-densitometric
method with an application of HPTLC plates and
mobile phase composed of n-butanol, acetic acid
and distilled water in a ratio of 15 : 5 : 1 (v/v/v) may
be successfully used for determination of substance
in three-component mixture in developed conditions
of analysis. Well separated peaks were obtained in
such conditions, which was confirmed by Rf values.
With wavelengths selected for measurements,
spectrophotometric and chromatographic methods are
specific for analyte represented by the studied com-
pounds. Specificity in spectrophotometric method was
determined comparing derivatives values according to
the relationship  (Rm ñ first derivative value of model
solution; Pf ñ first derivative value of pharmaceutical
formulation). It was found that they do not differ con-
siderably from value of 1 and are within the range
from 0.96 to 1.05, which proves almost identical
course of derivative curves for standard solutions and
pharmaceutical preparation solutions. It may be con-
cluded on this basis that placebo used for formation of
suitable drug form does not influence quantitative
determination of an active substance.
Well separated peaks of retardation factor val-
ues of Rf ~ 0.70, Rf ~ 0.78 and Rf ~ 0.85 for
quinapril, hydrochlorothiazide and losartan, respec-
tively, are observed on registered densitograms in
chromatographic-densitometric method. Satisfacto-
ry separation of the peaks is confirmed by resolution
factors Rs = 1.36 for quinapril and hydrochloroth-
iazide peaks, and Rs = 1.12 for hydrochlorothiazide
and losartan peaks (Figs. 5, 6)
Linearity is maintained in a wide range of con-
centrations, i.e., from 4.90 to 29.40 µg/mL for
quinapril, and from 3.10 to 18.60 µg/mL for
hydrochlorothiazide, as well as from 4.83 to 28.95
µg/mL for losartan potassium and from 1.24 to 7.44
µg/mL for hydrochlorothiazide, for spectrophoto-
metric method.
Linearity range determined by the chromato-
graphic-densitometric method was from 0.0313 to
2.00 mg/mL for quinapril, from 0.0306 to 0.49
mg/mL for losartan and from 0.0078 to 1.00 mg/mL
for hydrochlorothiazide. 
Linear determination coefficient does not
determine the linearity of calibration method in an
unequivocal manner. Therefore, Mandelís test was
used for linearity assessment. The obtained results
of linear and square adjustment prove linear adjust-
ment of calibration curve in all the cases except for
determination of hydrochlorothiazide using chro-
matographic-densitometric method. Normality of
residues distribution was confirmed using Shapiro-
Wilk test (20). Points of straight line crossing do not
diverge considerably from zero (Tab. 1).
Sensitivity of developed method is high, for
spectrophotometric method LOD was in the range
from 0.68 to 2.01 µg/mL and LOQ from 2.06 to 6.08
µg/mL. For chromatographic-densitometric method
LOD was in the range from 0.20 to 0.63 µg/spot and
LOQ from 0.61 to 1.91 µg/spot.
Percentage of recovery of the studied compo-
nents presented as the mean values for three levels
of concentrations is high, and in the range of 100 ±
5%, both in spectrophotometric and chromatograph-
ic-densitometric method. The results of determina-
tion for individual constituents are of similar preci-
sion, RSD is within a narrow range from 0.30 to
1.97% (Tab. 2).
The results obtained in the study are of a prac-
tical value and may be applied in drug quality con-
trol. 
The results of particular components determi-
nation do not diverge from declared values, and are
thus characterized by good precision and accuracy,
narrow confidence interval and beneficial values of
mean standard deviation (Sx), relative error (%Erel)
and relative standard deviation (RSD) (Tab. 3).
They may also be an indicator for wider application
of derivative spectrophotometry method and
HPTLC for complex drugs analysis.
CONCLUSIONS
Spectrophotometric and chromatographic-den-
sitometric methods have been proposed for the
determination of losartan potassium, quinapril
hydrochloride and hydrochlorothiazide present in
the complex pharmaceutical formulations. Spectro-
photometric method utilizes a ìzero-crossingî tech-
nique and the corresponding experimentally deter-
mined wavelengths. This technique enables to elim-
inate interferences between determined constituents
which are clearly visible in the zero order spectra.
The method is characterized by a wide linearity
range confirmed by statistical tests, high precision
(RSD in the range 0.30 - 1.44%), low values of LOD
and LOQ and specificity in relation to the matrix
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components. Separation conditions developed by a
chromatographic-densitometric method (stationary
phase and mobile phase) allow for a satisfactory
separation of components of the mixture (confirmed
by Rf values). Good separation of the constituents
enables qualitative and quantitative determination of
the three components in the analyzed mixture.
Analytical procedures presented in this manu-
script do not require complicated sample prepara-
tion, they are simple and quick to perform and can
be used in the quality control of medicinal products,
as an alternative to the pharmacopoeial methods.
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